AUA指南:肾脏肿块与局限性肾癌的评估、管理与随访(第一部分)
该AUA指南聚焦成人临床局限性肾脏肿块(含实性强化肿瘤及Bosniak 3/4复杂囊性病变)的评估、咨询与管理。指南基于更新文献综述(2021年修订),采用A/B/C证据等级及强/中/条件推荐,倡导个体化咨询与管理,强调部分肾切除术在cT1a病变中的优先地位,并更新了肾肿块活检、遗传咨询及辅助治疗的相关推荐。
要点
- 临床T1a病变优先推荐部分肾切除术,同时可选择性使用热消融(对≤3.0 cm肿瘤有效)。
- 肾肿块活检在评估中的作用不断演变,应个体化咨询。
- 提供肾根治性切除术的细化标准,以减少过度使用并避免不审慎的部分肾切除。
核心结论
- 临床局限性肾脏肿块的管理需综合考虑整体健康与合并症、肿瘤学因素、功能结局及不同管理策略的相对疗效与潜在并发症。
研究设计与样本
- 指南基于更新文献综述(2021年修订),证据等级分为A(高)、B(中)、C(低),推荐强度分为强、中、条件推荐;证据不足时提供临床原则与专家意见。
主要发现
- 临床局限性肾脏肿块的评估与管理取得较大进展,指南提供了关于评估与咨询(包括肾肿块活检不断演变的作用)的更新循证推荐。
- 鉴于临床、肿瘤学及功能特征的巨大变异性,未采用索引患者,专家组倡导个体化咨询与管理。
- 综述了干预选项(部分肾切除术、根治性肾切除术及热消融),包括比较效果与潜在并发症的最新数据。
- 优先考虑肿瘤学问题,同时认识到功能结局对生存者的重要性。
- 提供了根治性肾切除术的细化标准,以帮助减少过度使用并避免不审慎的部分肾切除。
关键数值与推荐
- 临床T1a病变推荐优先选择部分肾切除术,并可选择性使用热消融(对≤3.0 cm肿瘤疗效良好)。
- 遗传咨询推荐已修订,并讨论了辅助治疗的考虑。
- 主动监测与干预后随访在附篇中讨论。
临床怎么用
- 对临床局限性肾脏肿块患者进行个体化咨询与管理,综合考虑整体健康、合并症、肿瘤学因素及功能结局。
- 临床T1a病变优先选择部分肾切除术,对≤3.0 cm肿瘤可选择性使用热消融。
- 遵循细化标准选择根治性肾切除术,以减少过度使用并避免不审慎的部分肾切除。
- 根据修订后的推荐进行遗传咨询,并考虑辅助治疗的相关事宜。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This AUA Guideline focuses on evaluation/counseling/management of adult patients with clinically-localized renal masses suspicious for cancer, including solid-enhancing tumors and Bosniak 3/4 complex-cystic lesions. MATERIALS/METHODS: The Renal Mass and Localized Renal Cancer guideline underwent an update literature review which resulted in the 2021 amendment. When sufficient evidence existed, the body of evidence was assigned a strength rating of A (high), B (moderate), or C (low) for support of Strong, Moderate, or Conditional Recommendations. In the absence of sufficient evidence, additional information is provided as Clinical Principles and Expert Opinions (table 1[Table: see text]). RESULTS: Great progress has been made regarding the evaluation/management of clinically-localized renal masses. These guidelines provide updated, evidence-based recommendations regarding evaluation/counseling including the evolving role of renal-mass-biopsy (RMB). Given great variability of clinical/oncologic/functional characteristics, index patients are not utilized and the panel advocates individualized counseling/management. Options for intervention (partial-nephrectomy (PN), radical-nephrectomy (RN), and thermal-ablation (TA)) are reviewed including recent data about comparative-effectiveness/potential morbidities. Oncologic issues are prioritized while recognizing the importance of functional-outcomes for survivorship. Granular criteria for RN are provided to help reduce overutilization of RN while also avoiding imprudent PN. Priority for PN is recommended for clinical T1a lesions, along with selective utilization of TA, which has good efficacy for tumors≤3.0 cm. Recommendations for genetic-counseling have been revised and considerations for adjuvant-therapies are addressed. Active-surveillance and follow-up after intervention are discussed in an adjunctive article. CONCLUSION: Several factors require consideration during counseling/management of patients with clinically-localized renal masses including general health/comorbidities, oncologic-considerations, functional-consequences, and relative efficacy/potential morbidities of various management-strategies.
引用
- Campbell SC, Clark PE, Chang SS, et al. Renal Mass and Localized Renal Cancer: Evaluation, Management, and Follow-Up: AUA Guideline: Part I. J Urol. 2021. PMID: 34115547. doi:10.1097/JU.0000000000001911
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。